Annals of Allergy Asthma & Immunology最新文献

{"title":"Alpha-gal syndrome across the lifespan: Distinct pediatric clinical patterns and rural predominance in Midwestern patients.","authors":"Bailey Patrick, Victoria Salathe, Benjamin Warren Casterline","doi":"10.1016/j.anai.2025.08.013","DOIUrl":"10.1016/j.anai.2025.08.013","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144976991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaphylaxis to novel wheat products during wheat oral immunotherapy.","authors":"Chloe Citron, Amanda Schneider, Nancy DeGuzman, Kanwaljit Brar, Anna Nowak-Wegrzyn","doi":"10.1016/j.anai.2025.08.012","DOIUrl":"10.1016/j.anai.2025.08.012","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144977010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypes and follow-up of chronic cow's milk food protein-induced enterocolitis syndrome: A 16-year prospective observational study.","authors":"Giovanna Monti, Virginia Zarini, Emanuele Castagno, Claudia Bondone","doi":"10.1016/j.anai.2025.08.004","DOIUrl":"10.1016/j.anai.2025.08.004","url":null,"abstract":"<p><strong>Background: </strong>Chronic food protein-induced enterocolitis syndrome (cFPIES) is less well characterized than the acute form; the clinical features for defining the different clinical phenotypes have not been identified, and data on follow-up are lacking.</p><p><strong>Objective: </strong>To describe a population of infants with cow's milk cFPIES (CM-cFPIES), providing a definition of clinical phenotypes and their evolution between the onset and our observation and the natural history over time.</p><p><strong>Methods: </strong>A prospective observational study was conducted on all the patients with oral food challenge-diagnosed CM-cFPIES between January 2008 and January 2024. Descriptive analysis is reported.</p><p><strong>Results: </strong>A total of 39 patients were included. Neonatal onset was observed in 48.7%. We characterized and identified the following 3 clinical phenotypes: Severe from the very beginning (16/39, 41%), including 11 newborns; 86% of exclusively breastfed patients were part of this group. Mild (17/39, 43.6%) or moderate (6/39, 15.4%) at the onset, remaining stable over time (n = 8) or with progressive worsening (n = 15) until a severe form. The most prevalent symptom was intermittent vomiting, followed by diarrhea. Bloody stools were almost exclusively reported in newborns. Leukocytosis, neutrophilia, and metabolic acidosis were the most frequently observed laboratory features; eosinophil levels were significantly higher in newborns. Imaging was not specific and was misleading in some cases. Atypical CM-cFPIES was observed in 30.7% of patients; multiple FPIES was developed by 28.2%. Overall, 92% outgrew CM-cFPIES.</p><p><strong>Conclusion: </strong>Clinical suspicion of CM-cFPIES is difficult due to different phenotypes. Neonatal CM-cFPIES presents clinical and laboratory features that are partly different from those of the infant form. Exclusive breastfeeding might not be a protective factor. CM-cFPIES resolves in most children.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144977052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A call to action for penicillin allergy delabeling in patients with syphilis.","authors":"Aiwei Yan, Grace Koo, Christine Allocco, Elizabeth J Phillips, Cosby A Stone","doi":"10.1016/j.anai.2025.08.008","DOIUrl":"10.1016/j.anai.2025.08.008","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of varying childhood asthma definitions on incidence and clinical outcomes.","authors":"Amir Ghabousian, Gisele N Bezerra, Zhaozhong Zhu, Janice A Espinola, Ashley F Sullivan, Carlos A Camargo","doi":"10.1016/j.anai.2025.08.006","DOIUrl":"10.1016/j.anai.2025.08.006","url":null,"abstract":"<p><strong>Background: </strong>The absence of a standardized asthma definition in epidemiologic studies undermines the consistency of incidence estimates and the comparability of clinical outcomes.</p><p><strong>Objective: </strong>To evaluate the impact of integrating bronchodilator response (BDR) into parent-reported asthma definitions by comparing incidence, disease severity, control, and diagnostic performance across these definitions, and to assess the individual diagnostic performance of BDR and fractional exhaled nitric oxide in identifying asthma cases.</p><p><strong>Methods: </strong>We used data from a prospective cohort of 919 infants with severe (hospitalized) bronchiolitis to explore 4 asthma definitions: (1) broad, any physician diagnosis of asthma by age 6 years, as reported by parents; (2) epidemiologic, definition 1 plus either asthma medication use (eg, inhaled bronchodilator, inhaled corticosteroid, systemic corticosteroid, and montelukast) or asthma-related symptoms between ages 5.0 and 5.9 years; (3) alternative strict, definition 2 plus a post-BDR increase of 8% or greater in predicted forced expiratory volume in 1 second; and (4) strict, definition 2 plus a post-bronchodilator increase of more than 10% in predicted forced expiratory volume in 1 second. Outcomes were assessed across these definitions, and their diagnostic performance was compared with a physician reviewer's asthma diagnosis (reference standard).</p><p><strong>Results: </strong>The incidence rates for the 4 definitions were 37.2%, 27.7%, 13.2%, and 9.3%, respectively, with intermittent asthma severity classification following a similar pattern (72.4%, 65.5%, 56.0%, and 52.8%). Transitioning from the first to the fourth definition improved specificity and positive predictive value but reduced sensitivity, with no consistent trends being observed for asthma control across definitions.</p><p><strong>Conclusion: </strong>These findings suggest that incorporating BDR into parent-reported asthma definitions underestimates asthma incidence and identifies cases with worse clinical outcomes.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to inhaled corticosteroid medications after an asthma exacerbation and the risk of subsequent exacerbations.","authors":"Mina Khezrian, Marjan Kerkhof, Tham T Le, Tim Harrison, Tianshi David Wu, Bill Cook, Jonatan Hedberg, Kirsty Rhodes, Nicole Zubizarreta, Joshua Enxing, Trung N Tran","doi":"10.1016/j.anai.2025.08.007","DOIUrl":"10.1016/j.anai.2025.08.007","url":null,"abstract":"<p><strong>Background: </strong>Data on the duration of improved adherence to controller medications after an exacerbation and its impact on asthma outcomes are inconsistent.</p><p><strong>Objective: </strong>To describe levels and changes in adherence to inhaled corticosteroid (ICS)-containing medication after a severe exacerbation and the association with future exacerbation risk.</p><p><strong>Methods: </strong>This retrospective cohort study used data from Optum's deidentified Clinformatics Data Mart Database (October 2015-December 2023). Patients with asthma, 1 or more severe exacerbations, and adherence to ICS-containing therapy (proportion of days covered [PDC]) of less than 80% in the 3 months before an exacerbation were included. Primary and secondary end points were the annualized asthma exacerbation rate and the time to the first subsequent severe exacerbation. End points were compared between patients who improved adherence in the 3 months after the qualifying exacerbation to 80% or more and those who remained at PDC less than 80%. Inverse probability of treatment weighting accounted for between-group imbalances.</p><p><strong>Results: </strong>Of 68,398 participants, 85% stayed less than 80% PDC, whereas 15% improved to PDC 80% or more at 3 months after the qualifying exacerbation. Of patients with improved PDC, only 40%, 31%, and 22% maintained PDC 80% or more at 3 to 6, 6 to 9, and 9 to 12 months after the qualifying exacerbation, respectively. Improving adherence to PDC 80% or more in the 3 months after the qualifying exacerbation did not reduce annualized asthma exacerbation rate (rate ratio: 0.958 [95% CI 0.912-1.007]) or increase the time to the next exacerbation (hazard ratio: 0.997 [95% CI 0.954-1.041]). Results were consistent in sensitivity analyses.</p><p><strong>Conclusion: </strong>Improvement in adherence to ICS-containing therapy after a severe exacerbation was transient and not beneficial for exacerbation outcomes, indicating a need to consider alternative treatment strategies in patients with asthma.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mast cell conditions and drug allergy.","authors":"Bianca Olivieri, Patrizia Bonadonna","doi":"10.1016/j.anai.2025.07.030","DOIUrl":"10.1016/j.anai.2025.07.030","url":null,"abstract":"<p><p>Mast cell disorders, specifically systemic mastocytosis, are associated with an increased risk of drug hypersensitivity reactions. Among medications, nonsteroidal anti-inflammatory drugs are the most frequent triggers, followed by antibiotics and perioperative drugs. Although drug-induced reactions, particularly anaphylaxis, are a major concern, recent data suggest that the overall prevalence of severe reactions is relatively low. Nevertheless, drug avoidance behaviors remain frequent, often leading to unnecessary therapeutic restrictions. This review discusses the available evidence on drug hypersensitivity reactions in mastocytosis, focusing on the most frequent drug triggers and their management. Individualized assessment should be prioritized, relying on a detailed clinical history to guide decisions. In patients without a history of hypersensitivity, new treatments can often be introduced safely, whereas those with previous reactions may benefit from careful risk stratification, skin testing, or supervised drug provocation testing. A history-driven, evidence-based approach allows most patients with mast cell disorders to be treated effectively without unnecessary drug avoidance.</p>","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Communicating compassion in the face of grief and loss in allergy-immunology.","authors":"Marcus Shaker","doi":"10.1016/j.anai.2025.07.029","DOIUrl":"10.1016/j.anai.2025.07.029","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life evaluation of biologics in pediatric severe asthma using core outcome measures for severe asthma.","authors":"Francesca Galletta, Stefano Passanisi, Simone Foti Randazzese, Amelia Licari, Sara Manti","doi":"10.1016/j.anai.2025.07.027","DOIUrl":"10.1016/j.anai.2025.07.027","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophilic esophagitis","authors":"Timothy M. Buckey MD, MBE ,&nbsp;Jonathan M. Spergel MD, PhD","doi":"10.1016/j.anai.2025.04.017","DOIUrl":"10.1016/j.anai.2025.04.017","url":null,"abstract":"","PeriodicalId":50773,"journal":{"name":"Annals of Allergy Asthma & Immunology","volume":"135 2","pages":"Pages 125-126"},"PeriodicalIF":4.7,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}